Intermediate-Dose Ara-C/m-AMSA for Remission Induction and High-Dose Ara-C/m-AMSA for Intensive Consolidation in Relapsed and Refractory Adult Acute Myelogeneous Leukemia

Publisher Website
Google Scholar
Abstract
High-dose Ara-C regimens (HD-Ara-C) designed as intermittent infusions of 3 g/m2 over 1 — 3 h at 12-h intervals have shown good effectivity either as single-drug treatment or in combination with anthracyclines, m-AMSA, or L-asparaginase [1–5]. However, remission induction has been achieved at the expense of a considerable treatment-associated death rate. In our present approach we examine intermediate-dose Ara-C (IDAra-C) for treatment of refractory and relapsed acute AML. The dose reduction to 1 g/m2 performed in ID Ara-C was anticipated to decrease treatment-related toxicity, while treatment efficacy should not be impaired [6-8].